{"url_path":"/sec/inbp/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1016504/0001437749-26-015899-index.html","accession_number":"0001437749-26-015899","cik":"0001016504","ticker":"INBP","issuer_name":"INTEGRATED BIOPHARMA INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1016504/0001437749-26-015899-index.html","primary_entity_key":"0001016504","primary_entity_name":"INTEGRATED BIOPHARMA INC"},"word_count":723,"has_tables":true,"body_markdown":"inbp20260331_10q.htm\n\n0001016504\nINTEGRATED BIOPHARMA INC\nfalse\n--06-30\nQ3\n2026\n2,946\n485\n987\n485\n1,974\n0\n\n0.002\n0.002\n50,000,000\n50,000,000\n31,094,510\n31,094,510\n31,059,510\n31,094,510\n34,900\n34,900\n0\n28\n11\n6\n0\nhttp://fasb.org/us-gaap/2026#SecuredOvernightFinancingRateSofrMember\n2\n2\n2\n2\n2\n2\n2\n2\n3\n3\n0\n33\n12\n3\n10\n1\n3\n2\nfalse\nfalse\nfalse\nfalse\n\n00010165042025-07-012026-03-31\nxbrli:shares\n00010165042026-05-08\nthunderdome:item\niso4217:USD\n00010165042026-01-012026-03-31\n00010165042025-01-012025-03-31\n00010165042024-07-012025-03-31\niso4217:USDxbrli:shares\n00010165042026-03-31\n00010165042025-06-30\n0001016504inbp:VitaminRealtyLLCMember2026-03-31\n0001016504inbp:VitaminRealtyLLCMember2025-06-30\n0001016504us-gaap:CommonStockMember2025-06-30\n0001016504us-gaap:AdditionalPaidInCapitalMember2025-06-30\n0001016504us-gaap:RetainedEarningsMember2025-06-30\n0001016504us-gaap:TreasuryStockCommonMember2025-06-30\n0001016504us-gaap:CommonStockMember2025-07-012025-09-30\n0001016504us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30\n0001016504us-gaap:RetainedEarningsMember2025-07-012025-09-30\n0001016504us-gaap:TreasuryStockCommonMember2025-07-012025-09-30\n00010165042025-07-012025-09-30\n0001016504us-gaap:CommonStockMember2025-09-30\n0001016504us-gaap:AdditionalPaidInCapitalMember2025-09-30\n0001016504us-gaap:RetainedEarningsMember2025-09-30\n0001016504us-gaap:TreasuryStockCommonMember2025-09-30\n00010165042025-09-30\n0001016504us-gaap:CommonStockMember2025-10-012025-12-31\n0001016504us-gaap:AdditionalPaidInCapitalMember2025-10-012025-12-31\n0001016504us-gaap:RetainedEarningsMember2025-10-012025-12-31\n0001016504us-gaap:TreasuryStockCommonMember2025-10-012025-12-31\n00010165042025-10-012025-12-31\n0001016504us-gaap:CommonStockMember2025-12-31\n0001016504us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001016504us-gaap:RetainedEarningsMember2025-12-31\n0001016504us-gaap:TreasuryStockCommonMember2025-12-31\n00010165042025-12-31\n0001016504us-gaap:CommonStockMember2026-01-012026-03-31\n0001016504us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001016504us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001016504us-gaap:TreasuryStockCommonMember2026-01-012026-03-31\n0001016504us-gaap:CommonStockMember2026-03-31\n0001016504us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001016504us-gaap:RetainedEarningsMember2026-03-31\n0001016504us-gaap:TreasuryStockCommonMember2026-03-31\n0001016504us-gaap:CommonStockMember2024-06-30\n0001016504us-gaap:AdditionalPaidInCapitalMember2024-06-30\n0001016504us-gaap:RetainedEarningsMember2024-06-30\n0001016504us-gaap:TreasuryStockCommonMember2024-06-30\n00010165042024-06-30\n0001016504us-gaap:CommonStockMember2024-07-012024-09-30\n0001016504us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30\n0001016504us-gaap:RetainedEarningsMember2024-07-012024-09-30\n0001016504us-gaap:TreasuryStockCommonMember2024-07-012024-09-30\n00010165042024-07-012024-09-30\n0001016504us-gaap:CommonStockMember2024-09-30\n0001016504us-gaap:AdditionalPaidInCapitalMember2024-09-30\n0001016504us-gaap:RetainedEarningsMember2024-09-30\n0001016504us-gaap:TreasuryStockCommonMember2024-09-30\n00010165042024-09-30\n0001016504us-gaap:CommonStockMember2024-10-012024-12-31\n0001016504us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-31\n0001016504us-gaap:RetainedEarningsMember2024-10-012024-12-31\n0001016504us-gaap:TreasuryStockCommonMember2024-10-012024-12-31\n00010165042024-10-012024-12-31\n0001016504us-gaap:CommonStockMember2024-12-31\n0001016504us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001016504us-gaap:RetainedEarningsMember2024-12-31\n0001016504us-gaap:TreasuryStockCommonMember2024-12-31\n00010165042024-12-31\n0001016504us-gaap:CommonStockMember2025-01-012025-03-31\n0001016504us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001016504us-gaap:RetainedEarningsMember2025-01-012025-03-31\n0001016504us-gaap:TreasuryStockCommonMember2025-01-012025-03-31\n0001016504us-gaap:CommonStockMember2025-03-31\n0001016504us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001016504us-gaap:RetainedEarningsMember2025-03-31\n0001016504us-gaap:TreasuryStockCommonMember2025-03-31\n00010165042025-03-31\n0001016504us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\n0001016504us-gaap:EmployeeStockOptionMember2025-01-012025-03-31\n0001016504us-gaap:EmployeeStockOptionMember2025-07-012026-03-31\n0001016504us-gaap:EmployeeStockOptionMember2024-07-012025-03-31\n0001016504us-gaap:LandAndBuildingMember2026-03-31\n0001016504us-gaap:LandAndBuildingMember2025-06-30\n0001016504us-gaap:LeaseholdImprovementsMember2026-03-31\n0001016504us-gaap:LeaseholdImprovementsMember2025-06-30\n0001016504us-gaap:MachineryAndEquipmentMember2026-03-31\n0001016504us-gaap:MachineryAndEquipmentMember2025-06-30\n0001016504inbp:FullyDepreciatedPropertyMember2026-01-012026-03-31\n0001016504inbp:FullyDepreciatedPropertyMember2025-01-012025-03-31\n0001016504inbp:FullyDepreciatedPropertyMember2025-07-012026-03-31\n0001016504inbp:FullyDepreciatedPropertyMember2024-07-012025-03-31\n0001016504inbp:AmendedLoanAgreementMember2026-03-31\n0001016504inbp:AmendedLoanAgreementMember2025-06-30\n0001016504us-gaap:RevolvingCreditFacilityMember2025-04-15\n0001016504us-gaap:RevolvingCreditFacilityMemberinbp:ConvertibleEquipmentLineOfCreditMember2025-04-15\nxbrli:pure\n0001016504us-gaap:RevolvingCreditFacilityMember2025-04-152025-04-15\n00010165042025-04-152025-04-15\n0001016504us-gaap:RevolvingCreditFacilityMemberinbp:ConvertibleEquipmentLineOfCreditMember2025-04-152025-04-15\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:TwoCustomersMember2026-01-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:TwoCustomersMember2025-01-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer1Memberinbp:ContractManufacturingMember2026-01-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer2Memberinbp:ContractManufacturingMember2026-01-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer1Memberinbp:ContractManufacturingMember2025-01-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer2Memberinbp:ContractManufacturingMember2025-01-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:TwoCustomersMember2025-07-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:TwoCustomersMember2024-07-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2025-07-012026-03-31\n0001016504us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:OtherNutraceuticalBusinessMember2024-07-012025-06-30\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer1Memberinbp:ContractManufacturingMember2025-07-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer2Memberinbp:ContractManufacturingMember2025-07-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer1Memberinbp:ContractManufacturingMember2024-07-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer2Memberinbp:ContractManufacturingMember2024-07-012025-03-31\n0001016504us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-07-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:OtherNutraceuticalBusinessMember2025-01-012025-03-31\n0001016504us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer1Member2025-07-012026-03-31\n0001016504us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer2Member2024-07-012025-06-30\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer1Memberinbp:OtherNutraceuticalBusinessMember2026-01-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer2Memberinbp:OtherNutraceuticalBusinessMember2026-01-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer1Memberinbp:OtherNutraceuticalBusinessMember2025-01-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer2Memberinbp:OtherNutraceuticalBusinessMember2025-01-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:OtherNutraceuticalBusinessMember2025-07-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer1Memberinbp:OtherNutraceuticalBusinessMember2025-07-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer2Memberinbp:OtherNutraceuticalBusinessMember2025-07-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer3Memberinbp:OtherNutraceuticalBusinessMember2025-07-012026-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:OtherNutraceuticalBusinessMember2024-07-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer1Memberinbp:OtherNutraceuticalBusinessMember2024-07-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer2Memberinbp:OtherNutraceuticalBusinessMember2024-07-012025-03-31\n0001016504us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinbp:MajorCustomer3Memberinbp:OtherNutraceuticalBusinessMember2024-07-012025-03-31\n0001016504us-gaap:NumberOfEmployeesGeographicAreaMemberus-gaap:UnionizedEmployeesConcentrationRiskMember2026-01-012026-03-31\nutr:Y\n0001016504srt:MinimumMember2026-01-012026-03-31\n0001016504srt:MaximumMember2026-01-012026-03-31\n0001016504inbp:VitaminRealtyLLCMember2026-01-012026-03-31\n0001016504inbp:UnrelatedPartyMember2026-01-012026-03-31\n0001016504inbp:VitaminRealtyLLCMember2025-01-012025-03-31\n0001016504inbp:UnrelatedPartyMember2025-01-012025-03-31\n0001016504inbp:VitaminRealtyLLCMember2025-07-012026-03-31\n0001016504inbp:UnrelatedPartyMember2025-07-012026-03-31\n0001016504inbp:VitaminRealtyLLCMember2024-07-012025-03-31\n0001016504inbp:UnrelatedPartyMember2024-07-012025-03-31\n0001016504inbp:ChairmanChiefExecutiveOfficeAndMajorStockholderMember2026-01-012026-03-31\n0001016504inbp:TheirMotherMajorStockholderOfTheCompanyMember2026-01-012026-03-31\nutr:sqft\n0001016504inbp:ManhattanDrugCompanyMember2012-01-04\n0001016504inbp:ManhattanDrugCompanyMember2012-01-05\n0001016504inbp:ManhattanDrugCompanyMember2012-01-052012-01-05\n0001016504inbp:ManhattanDrugCompanyMember2022-07-15\n0001016504inbp:ManhattanDrugCompanyMember2022-07-012022-07-01\n0001016504inbp:ManhattanDrugCompanyMember2026-02-17\n0001016504inbp:ManhattanDrugCompanyMember2026-02-172026-02-17\n0001016504inbp:VitaminRealtyLLCMember2026-03-31\n0001016504inbp:VitaminRealtyLLCMember2025-06-30\n0001016504inbp:WarehouseLeaseMember2026-03-31\n0001016504inbp:TransportationEquipmentLeaseMember2026-03-31\n0001016504inbp:OfficeEquipmentLeasesMember2026-03-31\n0001016504inbp:WarehouseLeaseMember2025-06-30\n0001016504inbp:TransportationEquipmentLeaseMember2025-06-30\n0001016504inbp:OfficeEquipmentLeasesMember2025-06-30\n0001016504inbp:UnrelatedPartyMember2026-03-31\n0001016504inbp:UnrelatedPartyMember2025-06-30\n0001016504inbp:FirstAmericanCommercialBancorpIncMemberus-gaap:OfficeEquipmentMemberus-gaap:SubsequentEventMember2026-04-27\n0001016504inbp:FirstAmericanCommercialBancorpIncMemberus-gaap:OfficeEquipmentMemberus-gaap:SubsequentEventMember2026-04-272026-04-27\n0001016504inbp:UsBankMember2026-03-31\n0001016504inbp:UsBankMember2025-06-30\n0001016504inbp:StockOptionPlan2026Member2025-12-31\n0001016504inbp:StockOptionPlan2026Memberinbp:OfficersAndEmployeesMember2025-12-31\n0001016504inbp:StockOptionPlan2026Memberinbp:OfficersAndEmployeesMember2025-12-012025-12-31\n0001016504inbp:StockOptionPlan2026Membersrt:MinimumMemberinbp:OfficersAndEmployeesMember2025-12-012025-12-31\n0001016504inbp:StockOptionPlan2026Membersrt:MaximumMemberinbp:OfficersAndEmployeesMember2025-12-012025-12-31\n0001016504us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\n0001016504us-gaap:EmployeeStockOptionMember2025-01-012025-03-31\n0001016504us-gaap:EmployeeStockOptionMember2025-07-012026-03-31\n0001016504us-gaap:EmployeeStockOptionMember2026-03-31\n0001016504us-gaap:EmployeeStockOptionMembersrt:MinimumMember2026-01-012026-03-31\n0001016504us-gaap:EmployeeStockOptionMembersrt:MaximumMember2026-01-012026-03-31\n0001016504srt:MinimumMember2025-07-012026-03-31\n0001016504srt:MaximumMember2025-07-012026-03-31\n0001016504srt:EuropeMember2026-01-012026-03-31\n0001016504srt:EuropeMember2025-01-012025-03-31\n0001016504srt:EuropeMember2025-07-012026-03-31\n0001016504srt:EuropeMember2024-07-012025-03-31\n0001016504inbp:ContractManufacturingMembercountry:US2026-01-012026-03-31\n0001016504inbp:ContractManufacturingMemberus-gaap:NonUsMember2026-01-012026-03-31\n0001016504inbp:ContractManufacturingMember2026-01-012026-03-31\n0001016504inbp:ContractManufacturingMembercountry:US2025-01-012025-03-31\n0001016504inbp:ContractManufacturingMemberus-gaap:NonUsMember2025-01-012025-03-31\n0001016504inbp:ContractManufacturingMember2025-01-012025-03-31\n0001016504inbp:OtherNutraceuticalBusinessMembercountry:US2026-01-012026-03-31\n0001016504inbp:OtherNutraceuticalBusinessMemberus-gaap:NonUsMember2026-01-012026-03-31\n0001016504inbp:OtherNutraceuticalBusinessMember2026-01-012026-03-31\n0001016504inbp:OtherNutraceuticalBusinessMembercountry:US2025-01-012025-03-31\n0001016504inbp:OtherNutraceuticalBusinessMemberus-gaap:NonUsMember2025-01-012025-03-31\n0001016504inbp:OtherNutraceuticalBusinessMember2025-01-012025-03-31\n0001016504country:US2026-01-012026-03-31\n0001016504us-gaap:NonUsMember2026-01-012026-03-31\n0001016504country:US2025-01-012025-03-31\n0001016504us-gaap:NonUsMember2025-01-012025-03-31\n0001016504inbp:ContractManufacturingMembercountry:US2025-07-012026-03-31\n0001016504inbp:ContractManufacturingMemberus-gaap:NonUsMember2025-07-012026-03-31\n0001016504inbp:ContractManufacturingMember2025-07-012026-03-31\n0001016504inbp:ContractManufacturingMembercountry:US2024-07-012025-03-31\n0001016504inbp:ContractManufacturingMemberus-gaap:NonUsMember2024-07-012025-03-31\n0001016504inbp:ContractManufacturingMember2024-07-012025-03-31\n0001016504inbp:OtherNutraceuticalBusinessMembercountry:US2025-07-012026-03-31\n0001016504inbp:OtherNutraceuticalBusinessMemberus-gaap:NonUsMember2025-07-012026-03-31\n0001016504inbp:OtherNutraceuticalBusinessMember2025-07-012026-03-31\n0001016504inbp:OtherNutraceuticalBusinessMembercountry:US2024-07-012025-03-31\n0001016504inbp:OtherNutraceuticalBusinessMemberus-gaap:NonUsMember2024-07-012025-03-31\n0001016504inbp:OtherNutraceuticalBusinessMember2024-07-012025-03-31\n0001016504country:US2025-07-012026-03-31\n0001016504us-gaap:NonUsMember2025-07-012026-03-31\n0001016504country:US2024-07-012025-03-31\n0001016504us-gaap:NonUsMember2024-07-012025-03-31\n0001016504inbp:ContractManufacturingMember2026-03-31\n0001016504inbp:ContractManufacturingMembercountry:US2025-06-30\n0001016504inbp:OtherNutraceuticalBusinessMember2026-03-31\n0001016504inbp:OtherNutraceuticalBusinessMembercountry:US2025-06-30\n0001016504country:US2025-06-30\n\n \n\n \n\n \n\n**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington D.C. 20549**\n\n**____________**\n\n \n\n**FORM 10-Q**\n\n \n\n**☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\nFor the quarterly period ended March 31, 2026\n\n \n\n**OR**\n\n \n\n**☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\nFor the transition period from                     to\n\n \n\nCommission File Number 001-31668\n\n \n\n**INTEGRATED BIOPHARMA, INC.**\n\n*(Exact name of registrant, as specified in its charter)*\n\n \n\n**Delaware**  ******22-2407475**\n\n*(State or other jurisdiction of* *(I.R.S. Employer*\n\n*incorporation or organization)* *Identification No.)*\n\n \n\n**225 Long Ave., Hillside, New Jersey**         ******07205**\n\n*(Address of principal executive offices)*                  *(Zip Code)*\n\n \n\n**(888) 319-6962**\n\n*(Registrant*’*s telephone number, including Area Code)*\n\n \n\n**Not Applicable**\n\n*(Former name, former address and former fiscal year, if changed since last report)*\n\n \n\n**Securities registered pursuant to Section 12(b) of the Exchange Act:**\n\n \n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\nNone\n\nNone\n\nNone\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.\n\nYes ☑ No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).\n\nYes ☑ No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\n      \nSmaller reporting company ☑\n\nLarge accelerated filer ☐** ** \n \nAccelerated filer ☐** ** \n \nNon-accelerated filer  ☑\n \nEmerging growth company ☐** **  \n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \n\n \n\nIndicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).\n\nYes ☐**** No ☑\n\n \n\nAs of May 8, 2026, there were 31,059,610 shares of common stock, $0.002 par value per share, of the registrant outstanding.\n\n \n\n \n\n \n\n \n\n \n\n**INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES**\n\n \n\n**FORM 10-Q QUARTERLY REPORT**\n\n**For the Quarter Ended March 31, 2026**\n\n**INDEX**\n\n \n\n \n\n \n \n\n**Page**\n\n \n\n**Part I. Financial Information**"}